Intensity Therapeutics, Inc. (private) announced that the Company has established a collaboration agreement with the National Institute of Health’s National Cancer Institute (NCI). The Collaboration is primarily with the laboratory of Jay Berzofsky, MD, Ph.D. The collaboration will allow for an exchange of materials between the Company, its vendors and the NCI. “We are pleased to be collaborating with the world’s leading cancer research Institution” said Lewis H. Bender, President and CEO of Intensity Therapeutics. “Dr. Berzofsky is one of the foremost scientists in the field of cancer immunology and it is an honor to be collaborating with him and his department’s scientists.”

About Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. is a specialty pharmaceutical company whose mission is to greatly extend the lives of patients with solid tumor cancers. Late stage cancer consists of well-defined visible tumors and unseen micro-metastases. To have an effective treatment one must destroy both the existing large observable tumors as well as the unseen micrometastases. Intensity Therapeutics is developing such a treatment approach. The Company creates novel, proprietary formulations of proven chemotherapy drugs. The technology increases the drug’s tissue dispersion and cell penetration properties. These products when injected directly into the primary tumor and the major visible metastases result in significantly greater survival compared to conventionally delivered chemotherapy. Further information can be found at www.intensitytherapeutics.com